Mindset Pharma Discovers 3 New Next Generation Psychedelic Compounds

A Canadian company has now made discoveries with intriguing implications for the clinical psychedelic industry.

Wednesday, Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced the discovery of three new families of tryptamine-free psychedelic compounds.

The company says its research into new chemical structures outside the realm of conventional psychedelic drugs was undertaken with the intention of developing superior neuropsychiatric drugs.

Photo via Mindset Pharma

Read more: Mindset Pharma develops new patent-pending technology

Read more: Beond publishes “Ibogaine: A Clinical Summary”

Mindset Pharma is a Toronto-based research and development company dedicated to the discovery and development of psychedelic drugs for the treatment of psychiatric and neurological disorders.

Using a so-called fragment-based drug discovery (FBDD) method in unison with a specific medicinal chemistry strategy, Mindset scientists designed and developed three new small-scale “tryptamine-free scaffolds”. chemically unique molecules designated as Families 6, 7 and 8.

In addition, the company has filed provisional patent applications for these three drug families that have resulted in favorable freedom-to-operate (FTO) non-infringement searches. Mindset indicates that some of these new compounds could potentially exhibit improved central nervous system (CNS) penetration and efficacy when administered orally.

“Mindset’s leading drug discovery engine continues to deliver innovations that have the potential to help patients around the world with neuropsychiatric and neurological disorders. The discovery of new families 6, 7 and 8 demonstrates our commitment to expanding our research and development and strengthening our intellectual property (IP) portfolio beyond conventional tryptamines in the psychedelic field,” said James Lanthier, CEO of Mindset. Pharmaceuticals.

“The discovery of these novel families further expands our rich pipeline and provides a unique serotonin receptor profile supporting our goal of designing elegant new drug candidates with increased receptor selectivity and potency profiles. Preclinical screening of the new families has shown promising results so far and we look forward to advancing Mindset’s continued innovations in these chemically distinct new drug families.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Irene B. Bowles